Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer

British Journal of Clinical Pharmacology

Volumn 77, Issue 4, 2014, Pages 695-703

  Brauch, Hiltrud ^a,b   Schwab, Matthias ^a,b,c  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

breast cancer; CYP2D6; personalized medicine; pharmacogenetics; poor metabolizer; tamoxifen

Indexed keywords

CYTOCHROME P450 2D6; ENDOXIFEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR POS; GENOMIC DNA; PRODRUG; TAMOXIFEN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; PHARMACOLOGICAL BIOMARKER;

ARTICLE; CANCER HORMONE THERAPY; CHROMOSOME 22Q; CONCENTRATION RESPONSE; DOSE RESPONSE; EARLY CANCER; FEMALE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY LOSS; HUMAN; MEDICAL INFORMATION; METHODOLOGY; PATIENT CARE; PERSONALIZED MEDICINE; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; BREAST NEOPLASMS; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETICS; METABOLISM; PHARMACOGENETICS; PROCEDURES;

ANTINEOPLASTIC AGENTS, HORMONAL; BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CYTOCHROME P-450 CYP2D6; FEMALE; GENETIC TESTING; GENOTYPE; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; POSTMENOPAUSE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 84897861518     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12229     Document Type: Article

References (56)

1. Jordan VC,. Tamoxifen: catalyst for the change to targeted therapy. Eur J Cancer 2008; 44: 30-38.
2. Food and Drug Administration testimony: tamoxifen. 1998. Available at http://www.fda.gov/NewsEvents/Testimony/ucm115118.htm (last accessed 4 September 2013).
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 365: 1687-1717.
4. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R,; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomized trial. Lancet 2013; 381: 805-816.
5. Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, Fritz P, Simon W, Suman VJ, Ames MM, Safgren SL, Kuffel MJ, Ulmer HU, Boländer J, Strick R, Beckmann MW, Koelbl H, Weinshilboum RM, Ingle JN, Eichelbaum M, Schwab M, Brauch H,. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA 2009; 302: 1429-1436.
6. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M,. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters. J Clin Oncol 2013; 31: 176-180.
7. GLOBOCAN cancer fact sheets: breast cancer. 2008. Available at http://globocan.iarc.fr/factsheets/cancers/breast.asp (last accessed 4 September 2013).
8. Biomarker Definition Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
9. Goetz MP, Rae JM, Suman VJ, Safgren SL, Ames MM, Visscher DW, Reynolds C, Couch FJ, Lingle WL, Flockhart DA, Desta Z, Perez EA, Ingle JN,. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 2005; 23: 9312-9318.
10. Jordan VC,. New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer. Steroids 2007; 13: 829-842.
11. Jordan VC,. A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 2009; 69: 1243-1254.
12. Zanger UM, Schwab M,. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013; 138: 103-141.
13. Griese EU, Zanger UM, Brudermanns U, Gaedigk A, Mikus G, Mörike K, Stüven T, Eichelbaum M,. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 1998; 8: 15-26.
14. Zanger UM, Fischer J, Raimundo S, Stüven T, Evert BO, Schwab M, Eichelbaum M,. Comprehensive analysis of the genetic factors determining expression and function of hepatic CYP2D6. Pharmacogenetics 2001; 11: 573-585.
15. CYP2D6 nomenclature website. Available at http://www.cypalleles.ki.se/ cyp2d6.htm (last accessed 4 September 2013).
16. Hoskins JM, Carey LA, McLeod HL,. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 2009; 9: 576-586.
17. Brauch H, Mürdter TE, Eichelbaum M, Schwab M,. Pharmacogenomics of tamoxifen therapy. Clin Chem 2009; 55: 1770-1782.
18. Dezentjé VO, Guchelaar HJ, Nortier JW, van de Velde CJ, Gelderblom H,. Clinical implications of CYP2D6 genotyping in tamoxifen treatment for breast cancer. Clin Cancer Res 2009; 15: 15-21.
19. Brauch H, Jordan VC,. Targeting of tamoxifen to enhance antitumour action for the treatment and prevention of breast cancer: the 'personalised' approach? Eur J Cancer 2009; 45: 2274-2283.
20. Lash TL, Lien EA, Sørensen HT, Hamilton-Dutoit S,. Genotype-guided tamoxifen therapy: time to pause for reflection? Lancet Oncol 2009; 10: 825-833.
21. Higgins MJ, Stearns V,. CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep 2010; 12: 7-15.
22. Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G,. Breast International Group (BIG) 1-98 Collaborative GroupCYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trial. J Natl Cancer Inst 2012; 104: 441-451.
23. Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Sestak I, Cuzick J, Dowsett M, ATAC trialists. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 452-460.
24. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M,. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
25. Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A,. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
26. Nakamura Y, Ratain MJ, Cox NJ, McLeod HL, Kroetz DL, Flockhart DA,. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 1264.
27. Stanton V,. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. J Natl Cancer Inst 2012; 104: 1265-1266.
28. Pharoah PD, Abraham J, Caldas C,. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst 2012; 104: 1263-1264.
29. Castells A, Gusella JF, Ramesh V, Rustgi AK,. A region of deletion on chromosome 22q13 is common to human breast and colorectal cancers. Cancer Res 2000; 60: 2836-2839.
30. Hirano A, Emi M, Tsuneizumi M, Utada Y, Yoshimoto M, Kasumi F, Akiyama F, Sakamoto G, Haga S, Kajiwara T, Nakamura Y,. Allelic losses of loci at 3p25.1, 8p22, 13q12, 17p13.3, and 22q13 correlate with postoperative recurrence in breast cancer. Clin Cancer Res 2001; 7: 876-882.
31. Loo LW, Ton C, Wang YW, Grove DI, Bouzek H, Vartanian N, Lin MG, Yuan X, Lawton TL, Daling JR, Malone KE, Li CI, Hsu L, Porter PL,. Differential patterns of allelic loss in estrogen receptor-positive infiltrating lobular and ductal breast cancer. Genes Chromosomes Cancer 2008; 47: 1049-1066.
32. Schroth W, Hamann U, Fasching PA, Dauser S, Winter S, Eichelbaum M, Schwab M, Brauch H,. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification. Clin Cancer Res 2010; 16: 4468-4477.
33. Lim YC, Desta Z, Flockhart DA, Skaar TC,. Endoxifen (4-hydroxy-N- desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol 2005; 55: 471-478.
34. Johnson MD, Zuo H, Lee KH, Trebley JP, Rae JM, Weatherman RV, Desta Z, Flockhart DA,. Skaar TC Pharmacological characterization of 4-hydroxy-N- desmethyl tamoxifen, a novel active metabolite of tamoxifen. Breast Cancer Res Treat 2004; 85: 151-159.
35. Dehal SS, Kupfer D,. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997; 57: 3402-3406.
36. Desta Z, Ward BA, Soukhova NV, Flockhart DA,. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther 2004; 310: 1062-1075.
37. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC,. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res 2009; 69: 1722-1727.
38. Mürdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, Fasching PA, Fehm T, German Tamoxifen and AI Clinicians Group, Eichelbaum M, Schwab M, Brauch H,. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther 2011; 89: 708-717.
39. Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, Nikoloff DM, Hillman G, Fontecha MR, Lawrence HJ, Parker BA, Wu AH, Pierce JP,. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011; 89: 718-725.
40. Goetz MP, Suman VJ, Hoskin TL, Gnant M, Filipits M, Safgren SL, Kuffel M, Jakesz R, Rudas M, Greil R, Dietze O, Lang A, Offner F, Reynolds CA, Weinshilboum RM, Ames MM, Ingle JN,. CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res 2013; 19: 500-507.
41. Dezentje VO, van Schaik RHN, Vletter-Bogaartz JM, van der Straaten T, Wessels JAM, Kranenbarg EMK, Berns EM, Seynaeve C, Putter H, van de Velde CJH, Nortier JWR, Gelderblom H, Guchelaar HJCYP,. 2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial. Breast Cancer Res Treat 2013; 140: 363-373. published online June 11.
42. Irvin WJ Jr, Walko CM, Weck KE, Ibrahim JG, Chiu WK, Dees EC, Moore SG, Olajide OA, Graham ML, Canale ST, Raab RE, Corso SW, Peppercorn JM, Anderson SM, Friedman KJ, Ogburn ET, Desta Z, Flockhart DA, McLeod HL, Evans JP, Carey LA,. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011; 29: 3232-3239.
43. McLeod HL,. Cancer pharmacogenomocs: early promise, but concerted effort needed. Science 2013; 339: 1563-1566.
44. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA,. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30-39.
45. Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, Jin Y, Storniolo AM, Nikoloff DM, Wu L, Hillman G, Hayes DF, Stearns V, Flockhart DA,. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006; 80: 61-74.
46. Mauvais-Javis P, Baudot N, Castaigne D, Banzet P, Kuttenn F,. Trans-4-Hydroxytamoxifen concentration and metabolism after local percutaneous administration to human breast. Cancer Res 1986; 46: 1521-1525.
47. Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT,. Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram. Br J Cancer 2008; 99: 616-621.
48. Burstein HJ, Prestrud AA, Seidenfeld J, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Malin J, Mamounas EP, Rowden D, Solky AJ, Sowers MR, Stearns V, Winer EP, Somerfield MR, Griggs JJ, American Society of Clinical Oncology. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 2010; 28: 3784-3796.
49. Shah RR, Shah DR,. Personalized medicine: is it a pharmacogenetic mirage? Br J Clin Pharmacol 2012; 74: 698-721.
50. Food and Drug Administration, USA. Summary minutes of the meeting of the Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science. 2006. Available at http://www.fda.gov/ohrms/dockets/ac/06/minutes/2006- 4248m1.pdf (last accessed 12 January 2012).
51. The Medicines and Healthcare products Regulatory Agency. Tamoxifen for breast cancer: drug interactions involving CYP2D6, genetic variants, and variability in clinical response. Drug Safety Update 2010; 4: A1.
52. Bundesinstitut fuer Arzneimittel und Medizinprodukte (BfArM). Available at http://www.bfarm.de/SharedDocs/1-Downloads/DE/Pharmakovigilanz/stufenplverf/ tamoxifen-cyp2d6-bescheid.pdf?-blob=publicationFile (last accessed 4 September 2013).
53. Saladores PH, Precht J, Schroth W, Brauch H, Schwab M,. Impact of metabolizing enzymes on drug response of endocrine therapy in breast cancer. Expert Rev Mol Diagn 2013; 13: 349-365.
54. Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M,. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
55. The Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
56. Brauch H, Schroth W, Goetz MP, Mürdter TE, Winter S, Ingle JN, Schwab M, Eichelbaum M,. Reply to A.-S. Dieudonné et al. and J. M. Rae et al. J Clin Oncol 2013; 2013: 2755-2756. published online June 17.